News Feed Opinion Career Insight Dialogues Blog Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
October, 2024
October 2024
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
28293031  
Dose-Dense vs Standard Adjuvant Chemotherapy for High-Risk Early Breast Cancer
Photo from www.bcrf.org
Jul 21, 2024, 21:49

Dose-Dense vs Standard Adjuvant Chemotherapy for High-Risk Early Breast Cancer

Yakup Ergün, Medical Oncologist at Antalya City Hospital, shared on X, about a recent paper by Alexios Matikas et al., commenting:

“Dose-Dense vs Standard Adjuvant Chemotherapy for High-Risk Early Breast Cancer: Final Results of the PANTHER Trial
mFU: 10.3years
Dose-dense adjuvant regimen is statistically associated with better RFS, EFS, and DDFS. OS is not significant (HR:0.82).”

Tailored Dose-Dense Versus Standard Adjuvant Chemotherapy for High-Risk Early Breast Cancer: End-of-Study Results of the Randomized PANTHER Trial

Journal: Journal of Clinical Oncology

Author: Alexios Matikas, Volker Möbus, Richard Greil, Anne Andersson, Günther G. Steger, Michael Untch, Tommy Fornander, Per Malmström, Sabine Schmatloch, Hemming Johansson, Mats Hellström, Yvonne Brandberg, Michael Gnant, Sibylle Loibl, Theodoros Foukakis and Jonas Bergh

Image

Source: Yakup Ergün/X

Alexios Matikas Antalya City Hospital Breast Cancer cancer DDFS EFS Jonas Bergh OncoDaily Oncology PANTHER Trial RFS Richard Greil Theodoros Foukakis Volker Möbus Yakup Ergün
Special Coverage
Blog
Oct 27, 2024, 20:31
Wafik S. El-Deiry: Honoring Mikhail Blagosklonny, Who Courageously Battled Lung Cancer and Influenced Scientific Publishing and Cancer Research
Blog
Oct 27, 2024, 20:26
Mieke Van Hemelrijck: Task Force Stratallon for the AllergoOncology Working Group
Blog
Oct 27, 2024, 20:21
Manchester Cancer Research Centre - Non-Clinical PhD Studentships and Clinical Research Training Fellowships
Blog
Oct 27, 2024, 20:19
Genetics Adviser - American Society of Human Genetics Annual Meeting 2024
Blog
Oct 27, 2024, 20:17
Marcio Covas Moschovas: The first telesurgery in Angola with the MicroPort MedBot
Blog
Oct 27, 2024, 20:15
Paolo F. Borromeo: Honored to announce a partnership between Healthway Philippines and I Can Serve Foundation
Blog
Oct 27, 2024, 20:14
Children's Cancer Institute - Celebrating the appointment of four incredible researchers to Associate Professor
Blog
Oct 27, 2024, 20:12
Oncopedia is dedicated to documenting the rich history of Europe’s impact on cancer care
Blog
Oct 27, 2024, 20:10
Dimitrios Kalogeropoulos: The power of Large Language Models and AI in healthcare
Blog
Oct 27, 2024, 20:09
Why cancer care in Europe needs patients and doctors to make the best possible decisions with a personalised approach
Blog
Oct 27, 2024, 20:06
The Role of Lifestyle Modification in Enhancing Cancer Therapy Outcomes
Blog
Oct 27, 2024, 20:05
BCRF's commitment to research as a means of understanding breast cancer's origins